Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 98

Results For "NFI"

1019 News Found

Sun Pharma settles patent litigation for Revlimid
News | June 23, 2021

Sun Pharma settles patent litigation for Revlimid

Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Cipla to market Roche's Antibody Cocktail in India
Policy | May 25, 2021

Cipla to market Roche's Antibody Cocktail in India

The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19


Everest Organics launches 'Posaconazole' API
News | May 25, 2021

Everest Organics launches 'Posaconazole' API

Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients


Balaxi records Q4 FY21 revenue of Rs. 53 Cr
News | May 22, 2021

Balaxi records Q4 FY21 revenue of Rs. 53 Cr

Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday


NATCO signs licensing agreement with Lilly for Baricitinib
News | May 18, 2021

NATCO signs licensing agreement with Lilly for Baricitinib

Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India


Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
News | May 13, 2021

Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India

The agreement will help ensure wider reach and access to patients in India


Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
News | May 13, 2021

Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr

It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021


Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
News | May 10, 2021

Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib

Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19